Literature DB >> 21831642

Alhydrogel® adjuvant, ultrasonic dispersion and protein binding: a TEM and analytical study.

J Robin Harris1, Andrei Soliakov, Richard J Lewis, Frank Depoix, Allan Watkinson, Jeremy H Lakey.   

Abstract

Aluminium-based vaccine adjuvants have been in use since the 1920s. Aluminium hydroxide (alum) that is the chemical basis of Alhydrogel, a widely used adjuvant, is a colloid that binds proteins to the particular surface for efficient presentation to the immune system during the vaccination process. Using conventional TEM and cryo-TEM we have shown that Alhydrogel can be finely dispersed by ultrasonication of the aqueous suspension. Clusters of ultrasonicated aluminium hydroxide micro-fibre crystals have been produced (∼ 10-100 nm), that are significantly smaller than those present the untreated Alhydrogel (∼ 2-12 μm). However, even prolonged ultrasonication did not produce a homogenous suspension of single aluminium hydroxide micro-fibres. The TEM images of unstained and negatively stained air-dried Alhydrogel are very similar to those obtained by cryo-electron microscopy. Visualization of protein on the surface of the finely dispersed Alhydrogel by TEM is facilitated by prior ultrasonication. Several examples are given, including some of medical relevance, using proteins of widely ranging molecular mass and oligomerization state. Even with the smaller mass proteins, their presence on the Alhydrogel surface can be readily defined by TEM. It has been found that low quantities of protein tend to cross-link and aggregate the small Alhydogel clusters, in a more pronounced manner than high protein concentrations. This indicates that complete saturation of the available Alhydrogel surface with protein may be achieved, with minimal cross-linkage, and future exploitation of this treatment of Alhydrogel is likely to be of immediate value for more efficient vaccine production.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831642     DOI: 10.1016/j.micron.2011.07.012

Source DB:  PubMed          Journal:  Micron        ISSN: 0968-4328            Impact factor:   2.251


  14 in total

1.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

2.  Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.

Authors:  Susan B Manoff; Michele Sausser; Amy Falk Russell; Jason Martin; David Radley; Donna Hyatt; Christine C Roberts; Jason Lickliter; Janakan Krishnarajah; Andrew Bett; Sheri Dubey; Tyler Finn; Beth-Ann Coller
Journal:  Hum Vaccin Immunother       Date:  2019-06-03       Impact factor: 3.452

3.  Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.

Authors:  Haiyue Xu; Tinashe B Ruwona; Sachin G Thakkar; Yanping Chen; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

4.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

5.  Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Authors:  Allan Watkinson; Andrei Soliakov; Ashok Ganesan; Karie Hirst; Chris Lebutt; Kelly Fleetwood; Peter C Fusco; Thomas R Fuerst; Jeremy H Lakey
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

6.  Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.

Authors:  Richard L Shimp; Christopher Rowe; Karine Reiter; Beth Chen; Vu Nguyen; Joan Aebig; Kelly M Rausch; Krishan Kumar; Yimin Wu; Albert J Jin; David S Jones; David L Narum
Journal:  Vaccine       Date:  2013-04-24       Impact factor: 4.169

7.  From Stock Bottle to Vaccine: Elucidating the Particle Size Distributions of Aluminum Adjuvants Using Dynamic Light Scattering.

Authors:  Emma Shardlow; Matthew Mold; Christopher Exley
Journal:  Front Chem       Date:  2017-01-09       Impact factor: 5.221

Review 8.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want.

Authors:  Harm HogenEsch; Derek T O'Hagan; Christopher B Fox
Journal:  NPJ Vaccines       Date:  2018-10-10       Impact factor: 7.344

9.  Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response.

Authors:  Bo Wang; Xuanyi Wang; Yumei Wen; Jing Fu; Hongyang Wang; Zhangmei Ma; Yan Shi; Bin Wang
Journal:  Sci Rep       Date:  2015-12-09       Impact factor: 4.379

Review 10.  Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.

Authors:  Emma Shardlow; Matthew Mold; Christopher Exley
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-07       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.